{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:57:38Z","timestamp":1789178258951,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Immune checkpoint inhibitors (ICIs) have transformed the management of advanced solid tumors but can trigger severe immune-related adverse events (irAEs). Among the rarest and most life-threatening is hemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory syndrome driven by uncontrolled immune activation. Case Presentation: We report the case of an 80-year-old man with clear cell renal carcinoma with sarcomatoid features who developed secondary hemophagocytic lymphohistiocytosis (HLH) after receiving four cycles of adjuvant pembrolizumab therapy. Following four cycles of immunotherapy, he presented with persistent fever, pancytopenia, hyperferritinemia (&gt;49,000 ng\/mL), hypofibrinogenemia, and elevated soluble IL-2 receptor (&gt;7500 U\/mL), fulfilling at least five HLH-2004 diagnostic criteria. Despite treatment with high-dose corticosteroids and intravenous anakinra (100 mg every 6 h), his condition rapidly deteriorated, leading to multiorgan failure and death. Discussion: ICI-induced HLH is an exceptional but increasingly recognized irAE, with fewer than 30 pembrolizumab-related cases reported to date. Diagnosis is challenging due to its nonspecific presentation, which can mimic infection, hepatic toxicity, or disease progression. The pathogenesis is believed to involve excessive activation of cytotoxic T cells and cytokine storm. While established pediatric protocols (HLH-94, HLH-2004) guide management, adult cases often require individualized approaches using corticosteroids and cytokine-targeted therapies such as IL-1 or IL-6 blockade. Conclusions: HLH secondary to ICIs should be considered in the differential diagnosis of patients receiving immunotherapy who develop unexplained fever and cytopenia. Early recognition and prompt initiation of immunosuppressive therapy are critical to improving outcomes in this potentially fatal complication.<\/jats:p>","DOI":"10.3390\/reports8040256","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:34:01Z","timestamp":1764758041000},"page":"256","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pembrolizumab-Associated Hemophagocytic Lymphohistiocytosis in Clear Cell Renal Carcinoma: Case Report and Literature Review"],"prefix":"10.3390","volume":"8","author":[{"given":"Romina","family":"Pinto Valdivia","sequence":"first","affiliation":[{"name":"Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente, 182, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4606-2316","authenticated-orcid":false,"given":"Luis","family":"Posado-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente, 182, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Escribano","family":"Iglesias","sequence":"additional","affiliation":[{"name":"Pathology Department, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ant\u00fanez Plaza","sequence":"additional","affiliation":[{"name":"Radiodiagnosis Service, University Hospital of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Fonseca-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente, 182, 37007 Salamanca, Spain"},{"name":"Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.05.020","article-title":"New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?","volume":"66","author":"Garrido","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Naleid, N., Mahipal, A., and Chakrabarti, S. (2025). Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010229"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Patton, L., Monteith, B., Heffernan, P., Herzinger, T., and Wilson, B.E. (2024). Hemophagocytic lymphohistiocytosis\/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: A case study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1394543"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41199-020-0050-3","article-title":"Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: An immunotherapeutic challenge","volume":"5","author":"Kalmuk","year":"2020","journal-title":"Cancers Head Neck"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1111\/1346-8138.15566","article-title":"Hemophagocytic syndrome associated with pembrolizumab therapy successfully controlled by cyclosporin","volume":"47","author":"Sakai","year":"2020","journal-title":"J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/08998280.2021.1945353","article-title":"Hemophagocytic lymphohistiocytosis due to pembrolizumab therapy for adenocarcinoma of the lung","volume":"34","author":"Doyle","year":"2021","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhai, C., Jin, X., You, L., Yan, N., Dong, J., Qiao, S., Zhong, Y., Zheng, Y., and Pan, H. (2024). Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: A case report and systematic review. BMC Geriatr., 24.","DOI":"10.1186\/s12877-023-04625-3"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.21037\/tcr-22-154","article-title":"Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: Two case reports and a literature review","volume":"11","author":"Wei","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_13","first-page":"101097","article-title":"A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy","volume":"30","author":"Takahashi","year":"2020","journal-title":"Respir. Med. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40425-018-0365-3","article-title":"Hemophagocytic lymphohistiocytosis with immunotherapy: Brief review and case report","volume":"6","author":"Sadaat","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/jmedgenet-2018-105485","article-title":"Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism","volume":"56","author":"Snyder","year":"2019","journal-title":"J. Med. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00404-025-08078-4","article-title":"Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: A case report with literature review","volume":"312","author":"Olmes","year":"2025","journal-title":"Arch. Gynecol. Obs. Obstet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2169\/internalmedicine.3889-19","article-title":"Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma","volume":"59","author":"Akagi","year":"2020","journal-title":"Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.14740\/jh1033","article-title":"Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma","volume":"11","author":"Marar","year":"2022","journal-title":"J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/iju5.70058","article-title":"A Case of Hemophagocytic Lymphohistiocytosis During Immune Checkpoint Inhibitor Treatment for Metastatic Renal Cell Carcinoma, Complicated by Pancytopenia Attributed to Cytomegalovirus Infection","volume":"8","author":"Honda","year":"2025","journal-title":"IJU Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/mco.2024.2742","article-title":"Refractory insulin resistance and hemophagocytic lymphohistiocytosis following enfortumab vedotin treatment: A case report","volume":"20","author":"Rossignon","year":"2024","journal-title":"Mol. Clin. Oncol."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/256\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:14:51Z","timestamp":1764760491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["reports8040256"],"URL":"https:\/\/doi.org\/10.3390\/reports8040256","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}